During the past decade, Hôpital Saint Vincent de Paul conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 5 clinical trials were completed, i.e. on average, 9.3% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 3 clinical trials were completed. i.e. 9.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Saint Vincent de Paul" #1 sponsor was "Groupe Francophone des Myelodysplasies" with 11 trials, followed by "Lille Catholic University" with 9 trials sponsored, "The Lymphoma Academic Research Organisation" with 8 trials sponsored, "University Hospital, Lille" with 7 trials sponsored and "Centre Oscar Lambret" with 7 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Saint Vincent de Paul" #1 collaborator was "Celgene" with 3 trials as a collaborator, "Ministry of Health, France" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Janssen-Cilag Ltd." with 2 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Saint Vincent de Paul" are "Myelodysplastic Syndromes" (9 trials), "Multiple Sclerosis" (7 trials), "MDS" (5 trials), "Cancer" (3 trials) and "Acute Myeloid Leukemia (AML)" (2 trials). Many other conditions were trialed in "Hôpital Saint Vincent de Paul" in a lesser frequency.

Most popular intervention types in "Hôpital Saint Vincent de Paul" are "Drug" (47 trials), "Other" (15 trials), "Device" (6 trials), "Behavioral" (5 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Rituximab" (6 trials), "Azacitidine" (4 trials), "Lenalidomide" (4 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Saint Vincent de Paul" are 79 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hôpital Saint Vincent de Paul". undefined are not yet recruiting, 23 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in Hôpital Saint Vincent de Paul, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Saint Vincent de Paul, 3 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 15 trials that are defined as “Not Applicable".